Antineoplastic Drugs API (75)
Showing 49–60 of 75 products · Page 5 of 7
Mubritinib
Mubritinib (TAK-165) is a potent Neu (HER2) and Cdc2 p34 inhibitor with IC50 of 6 nM and 0.2μM, respectively. TAK 165
Nilotinib
Tasigna is a new kind of tumor targeting drug, which belongs to tyrosine kinase inhibitor. It is used to treat CML patients resistant to imatinib, and has a significant effect. Gleevec is a preferred drug developed by Novartis for the treatment of chronic myelogenous leukemia (CML). Nilotinib is improved from the molecular structure of imatinib, which has a stronger selectivity for bcr-abl kinase activity, a stronger inhibition of tyrosine kinase than imatinib by 30 times, and can inhibit the BCR-ABL mutant kinase activity resistant to imatinib. It can also inhibit the activity of kit and PDGFR kinase.
Nimustine Hydrochloride
Nimostine hydrochloride is a kind of pyrimidine nitrosourea anti-tumor drug. It is the main drug for the treatment of intracranial tumor and meningeal leukemia with other nitrosourea drugs, such as ramustine, carmustine, smeustine, lomustine, formustine, and estraustine sodium phosphate. It belongs to nitrosourea alkylating agent. It can alkylate DNA, prevent DNA repair, change RNA structure and target fine The structure and function of the protein and enzyme of the cell play an anti-tumor role. It can pass through the blood-brain barrier. Animal experiments showed that 7% - 16% of them entered CSF after intravenous drip, and the highest was 30%. After intravenous drip for 5 minutes, the drug began to distribute in the ventricles. After 30 minutes, the drug concentration in the cerebrospinal fluid reached the peak value with a half-life of 0.49 hours. Clinically, it can be used to treat brain tumor, lung cancer, gastric cancer, rectal cancer, esophageal cancer, colon cancer, chronic leukemia and lymphoma, etc. it can be used in combination with other anti-tumor drugs.
Octreotide
Octreotide is a kind of synthetic octapeptide ring compound used in digestive system. It is a homologue of natural somatostatin, has the pharmacological activity of natural somatostatin, and has long-term effect (the half-life of this product is 1.5 hours, and the natural somatostatin is 2-3 minutes). This product has selective inhibitory effect on the secretion of growth hormone, glucagon and insulin, which is stronger than natural somatostatin. The animal test shows that the inhibitory effect of this product on the release of growth hormone is 70 times of natural somatostatin and the inhibitory effect on insulin is 3 times of natural somatostatin after 15 minutes of intravenous injection. It can also inhibit the secretion of gastric acid, amylase, lipase and pepsin. It can slow down the passage time of the gastrointestinal tract, promote the absorption of water and electrolyte, have the contractive effect on the visceral blood vessels, reduce the visceral blood flow, reduce the blood flow of the liver, reduce the portal pressure and blood flow of the portal vein, reduce the excessive secretion of the intestinal tract, and enhance the absorption of water and Na + by the intestinal tract.
Olaparib
Olapani is a new oral poly ADP ribose polymerase (PARP) inhibitor. PARP includes the most important members of three protein families: PARP1, PARP2 and parp3. PARP enzymes are involved in normal cell homeostasis, such as DNA transcription, cell cycle regulation and DNA repair. The results of olaparine in vitro showed that the single drug treatment or platinum based chemotherapy could inhibit the growth of the selected tumor cell line and the tumor growth of human cancer mice xenotransplantation model. The cytotoxicity and antitumor activity of BRCA deficient mouse tumor cell lines were increased after treatment with olaparine. In vitro studies also showed that the cytotoxicity induced by olapamil may be related to the inhibition of PARP enzyme activity and the increase of parp-dna complex formation, leading to the destruction of cell dynamic balance and cell death.
Oxaliplatin
Oxaliplatin, also known as losadine and oxaliplatin, belongs to platinum derivatives. It can be used alone or in combination with fluorouracil in the treatment of colorectal cancer metastasis after the failure of fluorouracil treatment. It is the third generation of platinum anti-tumor complex after cisplatin and carboplatin, and the only drug with significant activity for colorectal cancer so far. The principle of action is to inhibit DNA synthesis and replication by generating alkylation complexes and acting on DNA to form cross-linking within and between chains. It can also inhibit the proliferation of ovarian cancer and melanoma cell lines.
Pelitinib
Pelitinib is a 3-cyanoquinoline pan-ErbB tyrosine kinase inhibitor with potential antineoplastic activity. EKB-569 irreversibly binds covalently to epidermal growth factor receptors (EGFR) ErbB-1, -2 and -4, thereby inhibiting receptor phosphorylation and signal transduction and resulting in apoptosis and suppression of proliferation in tumor cells that overexpress these receptors.
Pemetrexed Disodium
Pemetrexed disodium is a successful tumor drug developed by Eli Lilly. The patent protection period is until January 2017. Pemetrexed disodium is a multi-target anti folate preparation with pyrrolidine group as its core structure. It is a double inhibitor of nucleotide synthetase / dihydrofolate reductase. It can inhibit cell recovery by destroying the normal metabolism of folate dependence in cells It can block three different enzyme targets which are important for the survival of cancer cells at the same time, so as to inhibit the growth of tumor.
Pemetrexed Disodium Hepthydrate
Pemetrexed is chemically similar to folic acid and is in the class of chemotherapy medicine called folate antimetabolites.
Ponatinib
Panatinib is an anticancer drug. In December 2012, it was approved by FDA to be used in the treatment of adult chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph + acute lymphoblastic leukemia (all). It is mainly used to treat patients who have no effect on dasatinib or nilotinib treatment, or who cannot tolerate dasatinib or nilotinib, and patients who are not suitable for follow-up treatment of imatinib. It can also be used to treat patients with gene mutation ("T315I mutation"), which makes patients resistant to imatinib, dasatinib or nilotinib. It is also used to treat CML and Ph + all in adults who have not used other TKIs. At present, it is the only available drug for BCR ABL kinase T315I mutation.
Potassium oxonate
Purpose: composed of a cancer medicine S - 1, inhibits antitumor medicine for the side effects of fluoride
